Dr. Kelly Kaihara, from Mission Bio, reviews a series of publications from pharma and academic researchers that follow up on large-scale clinical trials and use single-cell DNA sequencing to better understand therapy resistance, remission, and relapse.
Publications reviewed include:
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Choe et al. Blood Advances 2020
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. DiNardo, C.D. et al. Blood 2020
Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Ediriwickrema, A. et al. Blood Advances 2020
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Gao, Y. et al. Cancer Discovery 2019
